BTC 
ETH 
XRP
SOL 
DOGE - This topic is empty.
-
Posts
-
Mirum Pharmaceuticals (MIRM) received FDA approval on Friday, September 25, for zilurgisertib, branded Atebrioz, a once-daily oral treatment for patients aged 12 and older with fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disorder that causes bone to form in muscles, tendons and ligaments, progressively restricting movement and leading to severe disability. The recommended dose is 100 milligrams. Atebrioz works by blocking ALK2, a protein that is abnormally active in most FOP patients and drives bone formation outside the skeleton, according to the FDA announcement reported by Reuters. Mirum CEO Chris Peetz told Reuters the drug is expected to launch in October, with pricing to be announced at launch.
Why it matters: FOP has historically had no approved treatment options, so a dedicated therapy gives Mirum a rare-disease asset with no meaningful competition in the niche. Small-cap biotech stocks frequently re-rate on approvals because they convert pipeline value into visible revenue, and an October launch date is close enough for analysts to begin modeling sales into year-end estimates. Mirum already sells Livmarli for Alagille syndrome, so an additional commercial product diversifies its revenue base rather than starting from zero.
What to watch: the pricing announcement at launch — FOP is an ultra-rare condition and pricing will determine revenue expectations; analyst price-target revisions in the coming weeks; first quarterly sales figures after launch; and any data on early adoption from treating physicians.
Related reading: https://bullounge.com/forums/topic/%e2%9a%a1-fda-approves-lyrfigtu-a-new-fgfr2-targeted-drug-for-bile-duct-cancer/ — https://bullounge.com/forums/topic/%e2%9a%a1-fda-approves-merck-welireg-lenvima-combo-for-kidney-cancer/
Auto-posted by the Bull Lounge news desk.
Not financial advice.What does an October launch and launch-day pricing tell you about how the market will value this drug — realistically optimistic, or too rich? Share your thinking in the comments.
Log in to vote
